Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation due to a combination of small airway disease and emphysema — destruction of alveolar walls. The underlying driver is chronic pulmonary inflammation, largely perpetuated by oxidative stress and an amplified innate immune response. MSC therapy is being studied as a way to break this inflammatory cycle.
The Mechanisms
Reduction of Inflammation
Chronic inflammation is a hallmark of COPD, leading to damage of lung tissues and worsening respiratory function. MSCs secrete anti-inflammatory cytokines such as IL-10 and TGF-β, suppressing chronic inflammation in the lungs. A study published in Thorax (2013) demonstrated that administering MSCs to mice with induced emphysema significantly reduced inflammation in lung tissues — the MSC-treated group showed decreased levels of pro-inflammatory cytokines (TNF-α and IL-6), resulting in improved respiratory function and reduced lung damage.
Regeneration of Damaged Lung Tissue
MSCs promote the regeneration of damaged lung tissues by secreting growth factors, including VEGF and HGF. A study in Respiratory Research (2017) observed that MSCs could promote repair of alveolar damage in an emphysema model. After MSC transplantation, treated animals showed signs of alveolar regeneration and improved lung elasticity.
Immune System Modulation
COPD is not only an inflammatory disease but an immune disorder, where dysregulated immune responses contribute to disease progression. MSCs modulate the immune response by promoting regulatory T-cells (Tregs) and reducing pro-inflammatory immune cells such as Th17 cells and neutrophils. A study in Stem Cells International (2018) found that MSC therapy reduced the number of neutrophils in COPD patients' lungs — neutrophil accumulation being a key factor in COPD exacerbations.
What to Expect
COPD patients at True Regen Medical are evaluated for FEV1/FVC ratio, GOLD classification, exacerbation history, and current medication burden. Patients with GOLD Stage II–III tend to show the strongest functional benefit. Stage IV (FEV1 < 30% predicted) patients can be evaluated, but expectations are calibrated accordingly. The goal is slowing further decline, reducing exacerbation frequency, and improving quality of life — not reversal of structural lung damage.